Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, discusses the current frontline treatment strategy for patients with multiple myeloma, highlighting the role of quadruplets and triplets. Dr Voorhees first comments on the importance of assessing patient eligibility for autologous stem cell transplantation (autoSCT), highlighting data from the DETERMINATION trial (NCT01208662). Following this, Dr Voorhees discusses the role of quadruplet therapies in transplant-eligible patients, as well as the role of triplet therapies in transplant-ineligible patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
6 ноя 2022
